+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A novel staging protocol for non-small cell lung cancers according to MRP-1/CD9, KAI1/CD82 and PETA-3/CD151 gene expression



A novel staging protocol for non-small cell lung cancers according to MRP-1/CD9, KAI1/CD82 and PETA-3/CD151 gene expression



Proceedings of the American Association for Cancer Research Annual Meeting 44: 473-474




(PDF emailed within 1 workday: $29.90)

Accession: 034312251

Download citation: RISBibTeXText


Related references

Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. Journal of Clinical Oncology 16(4): 1397-1406, 1998

A novel staging protocol for non-small cell lung cancer according to MRP-1/CD9 and KA11/CD82 gene expression. Proceedings of the American Association for Cancer Research Annual Meeting 39: 410, 1998

Relationship between expression of KAI1/CD82 gene in non-small cell lung cancer and metastasis. Journal of China Medical University 32(6): 519-521, 2003

Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Research 56(8): 1751-1755, 1996

Expression of KITENIN, a KAI1/CD82 binding protein and metastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasive behaviour. Oncology Reports 16(6): 1267-1272, 2006

Expression of CD82/KAI1 and HIF-1α in non-small cell lung cancer and their relationship to vasculogenic mimicry. Zhongguo Fei Ai Za Zhi 14(12): 918-925, 2012

Expression of Gal-3 and CD82/KAI1 proteins in non-small cell lung cancer and their clinical significance. Zhonghua Zhong Liu Za Zhi 35(2): 124-128, 2013

Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer. Archives of Iranian Medicine 15(11): 707-712, 2013

KAI1/CD82 and ME491/CD63 expression in non-small-cell carcinoma of the lung and prognosis. Nihon Kyobu Geka Gakkai 45(3): 398-401, 1997

KAI1/CD82, Metastasis Suppressor Gene as a Therapeutic Target for Non-Small-Cell Lung Carcinoma. Journal of Environmental Pathology, Toxicology and Oncology 36(3): 269-275, 2018

Nuclear factor-kappaB-dependent expression of metastasis suppressor KAI1/CD82 gene in lung cancer cell lines expressing mutant p53. Cancer Research 61(2): 673-678, 2001

Relationship between the levels of KAI1/CD82 and CD44 and the clinicopathological features of non-small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 27(2): 101-104, 2004

KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: An immunohistochemical analysis. Cancer 83(3): 466-474, 1998

Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines. Cancer Letters 157(2): 169-176, September 1, 2000

Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines. Oncology Reports 21(1): 159-164, 2009